Brief: Regenxbio Reports New Positive Interim Data From Phase I/II Affinity Duchenne® Trial Of Rgx-202
11/03/2026 16:48
March 11 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 REGENXBIO INC - NO SERIOUS ADVERSE EVENTS OBSERVED IN PHASE I/II STUDY REGENXBIO INC - PIVOTAL TOPLINE DATA EXPECTED IN Q2 2026 REGENXBIO INC - TO REQUEST PRE-BLA MEETING WITH FDA IN MID-2026 Source text: ID:nPn3HL4bwa Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics